37620-38-5

Basic information

• Product Name: (2E)-3-(1,3-benzodioxol-5-yl)-1-(4-methylphenyl)prop-2-en-1-one
• CAS NO: 37620-38-5
• Molecular Formula: C₁₇H₁₄O₃
• Molecular Weight: 266.2913
• Mol File: 37620-38-5.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 434°C at 760 mmHg
• Flash Point: 208.1°C
• Density: 1.225g/cm³
• Vapor Pressure: 9.8E-08mmHg at 25°C
• Refractive Index: 1.638
• CAS DataBase Reference: (2E)-3-(1,3-benzodioxol-5-yl)-1-(4-methylphenyl)prop-2-en-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: (2E)-3-(1,3-benzodioxol-5-yl)-1-(4-methylphenyl)prop-2-en-1-one(37620-38-5)
• EPA Substance Registry System: (2E)-3-(1,3-benzodioxol-5-yl)-1-(4-methylphenyl)prop-2-en-1-one(37620-38-5)

Safety Data

• Hazardous Substances Data: 37620-38-5(Hazardous Substances Data)

Usage

Description

(2E)-3-(1,3-benzodioxol-5-yl)-1-(4-methylphenyl)prop-2-en-1-one, commonly known as safrole, is a colorless or slightly yellow oily liquid with a sweet, spicy odor. It is a chemical compound that has various applications in the production of perfumes, soaps, and other chemicals.

Uses

Used in Perfume and Soap Industry:
Safrole is used as a fragrance ingredient in the perfume and soap industry due to its sweet, spicy odor. It imparts a pleasant scent to these products, enhancing their appeal to consumers.
Used in Chemical Synthesis:
Safrole is also used as a precursor in the synthesis of other chemicals. Its unique chemical structure allows it to be transformed into various compounds, making it a valuable intermediate in chemical manufacturing processes.
However, it is important to note that safrole has been classified as a controlled substance in many countries due to its potential for abuse as a precursor to the illegal drug MDMA (ecstasy). Additionally, it has been found to have carcinogenic effects in animal studies and may also have harmful effects on the liver and kidneys. As a result, its use and production are heavily regulated to minimize the risks to human health and the environment.

Upstream product

• 120-57-0 piperonal 
• 619-41-0 4-(bromoacetyl)toluene 
• 495-76-1 piperonol 
• 536-50-5 CH₃C₆H₄CH(CH₃)OH 
• 766-97-2 4-n-methylphenylacetylene 
• 1443526-81-5 1-(benzo[d][1,3]dioxol-5-yl)-3-(p-tolyl)prop-2-yn-1-ol 
• 1417658-61-7 5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide 
• 64376-20-1 3-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-1-(4-methoxy-phenyl)-propenone 
• 29668-44-8 2,3-dihydro-benzo[1,4]dioxin-6-carbaldehyde 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 122-00-9 para-methylacetophenone 

Downstream Products

• 1443527-35-2 3-(benzo[d][1,3]dioxol-5-yl)-1,3-di-p-tolylpropan-1-one 
• 1443527-10-3 (S)-3-(benzo[d][1,3]dioxol-5-yl)-1,3-di-p-tolylpropan-1-one 
• 1465270-12-5 C₂₀H₁₆O₂ 
• 1465270-30-7 C₂₇H₂₂O₄S 
• 1376396-17-6 5-(benzo[d][1,3]dioxol-5-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide 
• 835911-11-0 1-acetyl-5-(benzo[d][1,3]dioxol-5-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazole 
• 1376396-14-3 5-(benzo[d][1,3]dioxol-5-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazole-1-carbaldehyde 
• 1197386-06-3 2-(p-tolylthio)-4-(benzo[d][1,3]dioxol-6-yl)-6-p-tolylpyridine-3-carbonitrile 
• 76287-93-9 5-Benzo[1,3]dioxol-5-yl-3-p-tolyl-4,5-dihydro-isoxazole 
• 76287-99-5 5-benzo[1,3]dioxol-5-yl-3-p-tolyl-isoxazole 
• 84857-19-2 4-Benzo[1,3]dioxol-5-yl-6-p-tolyl-pyrimidin-2-ylamine 

Relevant articles and documents

Dihydropyrazole derivatives containing benzo oxygen heterocycle and sulfonamide moieties selectively and potently inhibit COX-2: Design, synthesis, and anti-colon cancer activity evaluation

Cyclooxygenase-2 (COX-2) as a rate-limiting metabolism enzyme of arachidonic acid has been found to be implicated in tumor occurrence, angiogenesis, metastasis as well as apoptosis inhibition, regarded as an attractive therapeutic target for cancer therapy. In our research, a series of dihydropyrazole derivatives containing benzo oxygen heterocycle and sulfonamide moieties were designed as highly potent and selective COX-2 inhibitors by computer-aided drug analysis of known COX-2 inhibitors. A total of 26 compounds were synthesized and evaluated COX-2 inhibition and pharmacological efficiency both in vitro and in vivo with multi-angle of view. Among them, compound 4b exhibited most excellent anti-proliferation activities against SW620 cells with IC50 of 0.86 ± 0.02 μM than Celecoxib (IC50 = 1.29 ± 0.04 μM). The results favored our rational design intention and provides compound 4b as an effective COX-2 inhibitor available for the development of colon tumor therapeutics.

Design, synthesis and biological evaluation of novel pyrazoline-containing derivatives as potential tubulin assembling inhibitors

Abstract A series of novel pyrazoline-containing derivatives (15-47) has been designed, synthesized and evaluated for their biological activities. Among them, compound 18 displayed the most potent antiproliferative activity against A549, MCF-7 and HepG-2 cells line (IC50 Combining double low line 0.07 μM, 0.05 μM, 0.03 μM, respectively) and the tubulin polymerization inhibitory activity (IC50 Combining double low line 1.88 μM), being comparable to CA-4. Furthermore, we also tested that compound 18 was a potent inducer of apoptosis in HepG-2 cells and it had cellular effects typical for microtubule interacting agents, causing accumulation of cells in the G2/M phase of the cell cycle. These studies, along with molecular docking, provided a new molecular scaffold for the further development of antitumor agents that target tubulin.

4,5-Dihydropyrazole derivatives containing oxygen-bearing heterocycles as potential telomerase inhibitors with anticancer activity

Telomere and telomerase were closely related to the occurrence and development of some cancers. After the key active site of telomerase was identified, to enhance the ability of dihydropyrazole derivatives to inhibit telomerase, we designed a series of novel 4,5-dihydropyrazole derivatives containing heterocyclic oxygen moiety based on previous studies. The telomerase inhibition assay showed that compound 10a displayed the most potent inhibitory activity with an IC50 value of 0.6 μM for telomerase. The antiproliferative assay showed that 10a exhibited high activity against human gastric cancer cell SGC-7901 with an IC50 value of 10.95 ± 0.60 μM. Flow cytometric analysis and western blot results showed that 10a induced both apoptosis and autophagy. A docking simulation showed that 10a could bind well to the active site of telomerase and act as a telomerase inhibitor. The 3D-QSAR model was also built to provide a more pharmacological understanding that could be used to design new agents with more potent telomerase inhibitory activity.